Tumour-initiating cells capable of self-renewal and differentiation, which are responsible for tumour growth, have been identified in human haematological malignancies 1,2 and solid cancers [3] [4] [5] [6] . If such minority populations are associated with tumour progression in human patients, specific targeting of tumour-initiating cells could be a strategy to eradicate cancers currently resistant to systemic therapy. Here we identify a subpopulation enriched for human malignant-melanoma-initiating cells (MMIC) defined by expression of the chemoresistance mediator ABCB5 (refs 7, 8) and show that specific targeting of this tumorigenic minority population inhibits tumour growth. ABCB5
1
Tumour-initiating cells capable of self-renewal and differentiation, which are responsible for tumour growth, have been identified in human haematological malignancies 1, 2 and solid cancers [3] [4] [5] [6] . If such minority populations are associated with tumour progression in human patients, specific targeting of tumour-initiating cells could be a strategy to eradicate cancers currently resistant to systemic therapy. Here we identify a subpopulation enriched for human malignant-melanoma-initiating cells (MMIC) defined by expression of the chemoresistance mediator ABCB5 (refs 7, 8) and show that specific targeting of this tumorigenic minority population inhibits tumour growth. ABCB5
1 tumour cells detected in human melanoma patients show a primitive molecular phenotype and correlate with clinical melanoma progression. In serial human-tomouse xenotransplantation experiments, ABCB5
1 melanoma cells possess greater tumorigenic capacity than ABCB5
2 bulk populations and re-establish clinical tumour heterogeneity. In vivo genetic lineage tracking demonstrates a specific capacity of ABCB5 1 subpopulations for self-renewal and differentiation, because ABCB5 1 cancer cells generate both ABCB5
1 and ABCB5 2 progeny, whereas ABCB5 2 tumour populations give rise, at lower rates, exclusively to ABCB5 2 cells. In an initial proof-of-principle analysis, designed to test the hypothesis that MMIC are also required for growth of established tumours, systemic administration of a monoclonal antibody directed at ABCB5, shown to be capable of inducing antibody-dependent cell-mediated cytotoxicity in ABCB5 1 MMIC, exerted tumour-inhibitory effects. Identification of tumour-initiating cells with enhanced abundance in more advanced disease but susceptibility to specific targeting through a defining chemoresistance determinant has important implications for cancer therapy.
Human malignant melanoma is a highly aggressive and drugresistant cancer 9 that shows tumour heterogeneity 10, 11 and contains cancer cell subsets with enhanced tumorigenicity 12, 13 . We predicted that the melanoma chemoresistance mediator ABCB5 (refs 7, 8) could represent a molecular marker defining tumorigenic MMIC, because its expression also characterizes progenitor cell subsets in physiological skin 14 . We first examined the relationship of ABCB5 to clinical malignant melanoma progression because of its close association with CD166 (ref. 7) , a marker of more advanced disease 15 . This was assessed by ABCB5 immunohistochemical staining of an established melanoma progression tissue microarray 16 representing four major diagnostic tumour types: benign melanocytic nevi, primary cutaneous melanoma, metastases to lymph nodes and metastases to viscera. We found that primary or metastatic melanomas expressed significantly more ABCB5 than benign melanocytic nevi, thick primary melanomas more than thin primary melanomas, and melanomas metastatic to lymph nodes more than primary lesions (Fig. 1a) , identifying ABCB5 as a molecular marker of neoplastic progression. Apparent heterogeneity in ABCB5 expression was noted in metastases, with greater staining in the lymph node than in visceral metastases. When assayed in single-cell suspensions derived from clinical melanomas (Supplementary Table 1 ), ABCB5 was also found to be consistently expressed in 7/7 specimen, with ABCB5
1 tumour cell frequency ranging from 1.6 to 20.4% (10.1 6 2.9%, mean 6 s.e.m.) (Fig. 1b , and Supplementary Table 1 ). Further characterization with respect to antigens indicative of a more primitive melanoma phenotype revealed expression of CD20 (also known as MS4A1) 12 in 4/7 specimens (cell frequency 0.4 6 0.2%, mean 6 s.e.m.), nestin/NES 17, 18 in 7/7 (28.7 6 7.3%), TIE1 (ref. 10) in 7/7 (22.9 6 6.2%), CD144 (VE-cadherin; also known as CDH5) 10 in 5/7 (0.5 6 0.3%) and BMPR1A 19, 20 in 7/7 (1.5 6 0.9%), and of the stromal marker CD31 (also known as PECAM1) 10 in 6/7 specimens (0.7 6 0.4%) (Fig. 1b) . Preferential expression by ABCB5 , showing significant differences in ABCB5-staining intensities (mean 6 95% confidence interval (CI); thin or thick nevi versus thin or thick primary melanomas, or versus lymph node or visceral metastases, P values , 0.001; thin versus thick primary melanomas, P 5 0.004; thin and thick primary melanomas versus lymph node metastases, P 5 0.001; lymph node versus visceral metastases, P 5 0.025; n, provided in figure) . The picture colour map corresponds to sample types represented in the core array: green, thin nevi; orange, thick nevi; violet, thin primary melanoma; blue, thick primary melanoma; pink, lymph node metastases; yellow, visceral metastases. The scanning view of ABCB5 staining of the entire array corresponds to the colour key. b, Flow cytometry analysis of ABCB5, CD20, nestin, TIE1, CD144, CD31 or BMPR1a expression in n 5 7 melanoma patients. c, Marker expression by ABCB5 1 or ABCB5 2 melanoma cells determined by flow cytometry (mean 6 s.e.m., n 5 4-7 patients).
Vol 451 | 17 January 2008 | doi:10.1038/nature06489 versus 24.2 6 4.8%, respectively, mean 6 s.e.m., P 5 0.026), TIE1 (64.5 6 7.6% versus 22.5 6 6.5%, P 5 0.002), VE-cadherin (12.7 6 6.4% versus 1.0 6 0.7%, P 5 0.016), and BMPR1A (40.9 6 6.9 versus 2.5 6 0.5%, P 5 0.001), but not for CD20 (0.0 6 0.0% versus 0.8 6 0.8%, NS) or CD31 (2.4 6 1.2% vs. 0.3 6 0.2%, NS) (Fig. 1c) . Expression of nestin, TIE1, VE-cadherin and BMPR1A by malignant ABCB5 1 or ABCB5 2 subpopulations within tumours was confirmed by analysis of genetically tracked fluorescent melanoma xenografts ( Supplementary Fig. 1 ). Histologically, ABCB5
1 cells correlated with non-melanized, undifferentiated regions, whereas melanized, more differentiated tumour areas were predominantly ABCB5 2 ( Supplementary Fig. 2a) .
To determine whether the subset defined by ABCB5 was enriched for MMIC, we compared the abilities of ABCB5 1 versus ABCB5 2 melanoma cells to initiate tumour formation in vivo, using primary-patient-derived tumour cells in serial human-to-NOD/ SCID mouse xenotransplantation experiments. ABCB5-dependent cell sorting was performed using immunomagnetic selection [4] [5] [6] [7] , followed by confirmation of purity and viability of sorted populations as shown in Supplementary Fig. 3 . Groups of mice were transplanted with replicate (n 5 6-11) inocula of unsegregated, ABCB5 Fig. 2b ) and the concurrent demonstration in genetic lineage tracking experiments that ABCB5 2 melanoma cells do not generate ABCB5 1 progeny (Fig. 2h) . Comparison of the cellular diversity of clinical patient tumours with ABCB5
1 -derived primary and secondary xenografts revealed that ABCB5
1 subpopulations re-established parent tumour heterogeneity as determined by flow cytometry (ABCB5 positivity 9.0 6 3.5% (mean 6 s.e.m.) in parent melanomas and 8.8 6 1.7% and 13.1 6 3.2% in corresponding primary and secondary ABCB5
1 -cell-derived xenografts, respectively) (Fig. 2c, Supplementary Fig. 2c ). In summary, these findings establish that MMIC frequency is markedly enriched in the melanoma minority population defined by ABCB5 and demonstrate in vivo self-renewal and differentiation capacity of this subset.
To examine the relative tumour growth contributions of coxenografted ABCB5
1 and ABCB5 2 subpopulations directly, and to confirm ABCB5
1 self-renewal and differentiation capacity, we isolated ABCB5 1 or ABCB5 2 cells from stably transfected G3361 melanoma cell line variants expressing either red fluorescent protein (DsRed) or enhanced yellow-green fluorescent protein (EYFP), respectively-a model system designed to allow in vivo genetic lineage tracking. We found that xenotransplantation of ABCB5

/ DsRed and ABCB5
2 /EYFP fluorochrome-transfected co-culturesreconstituted at 14.0 6 3.0% and 86.0 6 3.0% relative abundance (mean 6 s.d., n 5 6), respectively-to NOD/SCID mice resulted in time-dependent, serially increasing relative frequencies of DsRed ( Fig. 2e, f, g ). These findings establish greater tumorigenicity of ABCB5 1 subsets in a competitive tumour development model. They further indicate that tumour-initiating cells may also drive more differentiated and otherwise non-tumorigenic cancer bulk populations to contribute, albeit less efficiently, to a growing tumour mass. The capacity of non-tumour-initiating cancer cell populations to undergo a limited number of replications is consistent with previous findings in other solid tumours [3] [4] [5] 21 . Experimental tumours also contained DsRed/EYFP double-positive melanoma cells (Fig. 2e, g ), indicating that ABCB5 2 tumour populations. These findings confirm the existence of a tumour hierarchy in which ABCB5
1 melanoma cells, enriched for MMIC, self-renew and give rise to more-differentiated ABCB5 2 tumour progeny. To dissect further and mechanistically whether the ABCB5-defined, MMIC-enriched minority population is also required for tumorigenicity when unsegregated cancer populations are xenografted, we examined whether selective killing of this cell subset can inhibit tumour growth and formation. We administered a monoclonal antibody directed at ABCB5 (refs 7, 14) in a human to the nude mouse melanoma xenograft model, because murine immunoglobulin G1 monoclonal antibodies trigger cellular immune effector functions 22 and because nude as opposed to NOD/SCID mice are capable of tumour cell killing by antibody-dependent cell-mediated cytotoxicity (ADCC) 23 . Anti-ABCB5 monoclonal antibody treatment resulted in significantly inhibited tumour growth compared to that determined in control-monoclonal-antibody-treated or untreated mice over the course of a 58-day observation period (tumour volume for anti-ABCB5-treated (n 5 11 mice, no death during the observation period; 23 6 16 mm 3 ; mean 6 s.e.m.) versus control-monoclonal-antibody-treated (n 5 10 mice, excluding 1 death; 325 6 78 mm 3 ), P , 0.01; versus untreated (n 5 18 mice, excluding 1 death; 295 6 94 mm 3 ), P , 0.001, see Methods for test used) (Fig. 3a) . Control monoclonal antibody treatment showed no significant difference compared to no treatment (Fig. 3a) . Anti-ABCB5 monoclonal antibody treatment also significantly inhibited tumour formation, with tumours detected in only 3/11 anti-ABCB5-treated mice versus 10/10 control-antibody-treated mice and 18/18 untreated control animals (P , 0.01 and P , 0.001, respectively) (Fig. 3b) . Human melanoma xenografts grown in untreated nude mice, like those in NOD/SCID recipients, showed tumour heterogeneity for ABCB5 (Supplementary Fig. 4a ). Immunohistochemical examination of tumours that successfully grew in the presence of ABCB5 monoclonal antibody revealed that these tumours still contained ABCB5
1 cells (Supplementary Fig. 4b ), indicating that ABCB5
1 MMIC had not been fully eradicated. On termination of monoclonal antibody administration, one tumour occurrence was noted among the eight ABCB5-treated mice that had not developed a tumour during an additional eight-month observation period, indicating prolonged inhibition of tumour-initiating cells.
To determine the mechanism of anti-ABCB5 monoclonalantibody-mediated inhibition of tumour formation and growth, the immune effector responses ADCC and complement-dependent cytotoxicity (CDC) were assessed, as described 24 . Anti-ABCB5 monoclonal antibody but not isotype control monoclonal antibody significantly induced ADCC-mediated melanoma target cell death (2.1 6 0.4% versus 0.2 6 0.2%, respectively, mean 6 s.e.m., P , 0.05) in a melanoma subpopulation comparable in size to the ABCB5-expressing subset 7 (Fig. 3c) . Addition of serum to anti-ABCB5-treated cultures in the absence of effector cells, or addition of monoclonal antibody alone did not induce significant cell death compared to controls (results not illustrated), precluding CDC or direct toxic monoclonal antibody effects as significant causes of tumour inhibition. We next analysed the effects of ABCB5 targeting on established human-to-nude mouse melanoma xenografts (n 5 13 derived from three distinct patients and n 5 10 derived from established melanoma cultures) to test the hypothesis that negative selection for MMIC by ADCC-mediated ABCB5 1 cell ablation inhibits tumour growth, as would be anticipated in a dynamic in vivo situation if the ABCB5 1 melanoma subset is critical to robust tumorigenesis. In vivo anti-ABCB5 monoclonal antibody administration, started 14 days following tumour cell inoculation when xenografts were established (day 0), abrogated the significant tumour growth observed in isotypecontrol-monoclonal-antibody-treated or untreated groups over the course of a 21-day treatment period (P , 0.001 and P , 0.001, respectively) and significantly inhibited mean tumour volume compared to that determined in either control-treated or untreated mice (tumour volume for anti-ABCB5-treated (n 5 23 mice; 32.7 6 9.4 mm 3 ; mean 6 s.e.m.) versus control-treated (n 5 22 mice; 226.6 6 53.8 mm 3 ), P , 0.001; versus untreated (n 5 22 mice; 165.4 6 36.9 mm 3 ), P , 0.01, see Methods for test used) (Fig. 3d) . The inhibitory effects of ABCB5 monoclonal antibody were also statistically significant when the subsets of freshly patient-derived melanoma xenograft tumours were analysed independently, with abrogation of the significant tumour growth observed in isotypecontrol-monoclonal-antibody-treated or untreated groups (P , 0.05 and P , 0.001, respectively) and significantly inhibited mean tumour volume compared to that determined in either control-treated or untreated mice (anti-ABCB5-treated (n 5 13 mice; 29.6 6 9.2 mm 3 ) versus control-treated (n 5 12 mice; 289.2 6 91.8 mm 3 ), P , 0.05; versus untreated (n 5 12 mice; 222.9 6 57.5 mm 3 ), P , 0.001) (Fig. 3d) . Control monoclonal antibody treatment showed no significant effects on tumour growth or tumour volume compared to no treatment in any of the groups analysed. The animals were euthanized following the treatment interval, as required by the applicable experimental animal protocol because of tumour burden and disease state in the patient-derived tumour control groups (measured maximal tumour volume, 971.5 mm 3 ). Immunohistochemical analysis of anti-ABCB5-treated patient-derived melanoma xenografts revealed only small foci of ABCB5 expression (overall ,1% of cells) (focal area of positivity shown in Fig. 3e ), corresponding to in vivo bound anti-ABCB5 monoclonal antibody in an adjacent section. An additional adjacent section stained for CD11b disclosed macrophage infiltration, corresponding to regions of anti-ABCB5 monoclonal antibody localization, which frequently bordered zones of cellular degeneration and necrosis (Fig. 3e) . In contrast, control-treated xenografts revealed 10-15% ABCB5-reactive cells, secondary anti-immunoglobulin monoclonal antibody failed to localize to the respective regions in an adjacent section but detected regions of intravascular murine immunoglobulin, and CD11b 1 macrophages failed to infiltrate the tumour tissue (Fig. 3e) . Similar effects were observed in cell-linederived melanoma xenografts ( Supplementary Fig. 4c, d) , with enhanced tumour necrosis in anti-ABCB5-treated versus isotypecontrol-monoclonal-antibody-treated animals (30-40% versus ,5% necrotic cells, respectively) ( Supplementary Fig. 4c ). These findings further support the notion that the ABCB5-defined, MMIC-enriched minority population is required for tumorigenicity.
Because ABCB5 represents a possible chemoresistance mechanism 7, 8 , our findings provide evidence for a new, potentially critical link between tumour-initiating cells, cancer progression and chemoresistance in a solid malignancy 25 , raising the possibility that ABCB5 1 MMIC may be responsible both for the progression and chemotherapeutic refractoriness of advanced malignant melanoma, and that MMIC-targeted approaches might therefore ultimately represent novel and translationally relevant therapeutic strategies to disseminated disease. Broader examination of a larger array of clinical specimen is warranted to establish further ABCB5 as a universal MMIC marker and robust candidate therapeutic target. Whether related ABC members 26, 27 might also represent prospective markers of tumour-initiating cells, or whether ABCB5 might represent such a marker in additional malignancies, such as breast cancer, in which it is known to be clinically expressed and specifically downregulated with epigenetic differentiation therapy 28 , requires further study.
Although MMIC are enriched in the melanoma subpopulations defined by ABCB5, clearly not every ABCB5 1 cell represents a MMIC, because purified populations did not invariably form tumours. Our finding that ABCB5 serves as a molecular marker for MMIC is consistent with the demonstration that ABCB5 expression is closely co-regulated with melanotransferrin, a molecule also associated with melanoma growth 29 . The tumour-initiating-cell frequency determined in malignant melanoma is approximately 19-fold lower than that, for example, determined in colon cancer 5 . Tumorigenicity in human-to-mouse xenotransplantation experiments, and as a result calculated stem cell frequency estimates, might vary with the applied experimental conditions, such as the tissue site of xenotransplantation, or the presence or absence of re-activated immune effector mechanisms in recipient immunodeficient mice 30 . Alternatively, inherent differences between stem cell frequencies in distinct malignancies could account for the observed difference. The per cent positivity of tumour cells identified by the prospective marker ABCB5 in clinical melanomas parallels those obtained for the CD133 marker, which detects subpopulations enriched for tumour-initiating cells at similar relative frequencies in brain cancer 4 and colon cancer 5, 6 , but likewise does not permit tumour-initiatingcell identification at the clonal level. Further studies are needed to reveal whether tumour-initiating cells can be molecularly defined at the single-cell level in a solid malignancy, or whether more than one cell is necessary for tumour initiation. Our results represent a significant step towards this goal in human malignant melanoma, and provide a basis to elucidate further, and eventually therapeutically target, the specific molecular pathways responsible for tumorigenicity, tumour progression and chemoresistance in tumour-initiating cells.
METHODS SUMMARY
Melanocytic tumour progression tissue microarray. Correlation of ABCB5 expression with melanoma progression was examined using an established microarray 16 and the Chromavision Automated Cellular Imaging System to quantify ABCB5 and control immunostaining intensities. Tumour cell isolation and flow cytometry. Clinical melanoma cells were derived from surgical specimen according to IRB-approved human subjects research protocols. Single-cell suspensions were generated using collagenase. ABCB5 expression was determined by flow cytometry, and ABCB5 1 and ABCB5 2 subpopulations were generated using anti-ABCB5 monoclonal antibody labelling and magnetic-bead cell sorting as described 7, 14 . Purity and viability of cell isolates were determined using CD31 and CD45 staining, propidium iodide staining and the calcein-AM assay followed by flow cytometry. Human melanoma xenotransplantation and ABCB5 targeting. NOD/SCID and Balb/c nude mice were maintained under defined conditions in accordance with institutional guidelines and experiments were performed according to approved experimental protocols. For tumorigenicity studies, unsegregated, ABCB5 1 , or ABCB5 2 melanoma cells were injected subcutaneously into flanks of recipient NOD/SCID mice. For MMIC targeting experiments, unsegregated melanoma cells were xenografted subcutaneously into recipient Balb/c nude mice and animals were injected i.p. with anti-ABCB5 monoclonal antibody 7, 14 or control monoclonal antibody (500 mg per injection, respectively) bi-weekly starting 24 h before melanoma xenotransplantation or 14 days post tumour cell inoculation, when tumours were established. Tumour formation/growth was assayed as a time course for the duration of the experiment or until excessive tumour burden or disease state required protocol-stipulated euthanasia. ADCC was assessed in vitro as described 24 and in vivo by histological analysis of tumourinfiltrating immune effector cells. In vivo genetic lineage tracking. 
METHODS
Melanoma cells and culture methods. The ABCB5-expressing G3361 human malignant melanoma cell line 7, 14 , derived from a single tumour cell cloned in soft agar, was provided by E. Frei III and cultured as previously described 7 . The G3361/DsRed and G3361/EYFP cell lines were generated by stable transfection of G3361 melanoma cells with either Discosoma sp. red fluorescent protein (DsRed) or the enhanced yellow-green variant (EYFP) of the Aequorea victoria green fluorescent protein (GFP) in conjunction with the simian virus 40 large T-antigen nuclear retention signal, using pDsRed-Nuc or pEYFP-Nuc mammalian expression vectors also containing a neomycin resistance cassette (BD Biosciences) and the Lipofectamine 2000 reagent (Invitrogen), as previously described 14 . Clonal G3361/DsRed and G3361/EYFP cultures were generated from stably transfected cultures by limiting dilution. Clinical melanoma cells (n 5 7 patients) were freshly derived from surgical specimens according to human subjects research protocols approved by the IRBs of the University of Würzburg Medical School or the Wistar Institute. Antibodies. The specific IgG1k anti-ABCB5 monoclonal antibody (mAb) 3C2-1D12 (refs 7, 14) was used in the herein reported studies. Unconjugated or FITCconjugated MOPC-31C mouse isotype control mAbs, FITC-conjugated goat anti-mouse IgG secondary Ab, phycoerythrin (PE)-conjugated anti-human CD20, anti-human and anti-mouse CD31, anti-human and anti-mouse CD45, and isotype control mAbs were purchased from Pharmingen. Allophycocyanin (APC)-conjugated and PE-conjugated secondary mAbs were purchased from eBioscience. Unconjugated anti-human TIE1, anti-human BMPR1A, PEconjugated anti-human VE-cadherin and anti-human nestin mAbs were from R&D Systems. The following antibodies were used for immunohistochemistry or immunofluorescence staining: mouse anti-ABCB5 mAb 7, 14 , HRP-conjugated horse anti-mouse IgG secondary Ab, HRP-conjugated horse anti-goat IgG secondary Ab and HRP-conjugated goat anti-rabbit IgG secondary Ab (Vector Laboratories), FITC-conjugated rabbit anti-mouse IgG secondary Ab (ZYMED Laboratories), unconjugated rabbit anti-human VE-cadherin Ab (provided by Cell Signaling Technology), mouse control IgG Abs (DAKO), goat anti-human TIE1 Ab (Neuromics), rat anti-mouse CD11b Ab and rat anti-mouse CD31 Ab (BD Biosciences Pharmingen), rabbit anti-human CD31 Ab (Bethyl Laboratories), donkey anti-mouse IgG-AF488, donkey anti-rabbit IgG-AF594, donkey anti-rat IgG-AF594 and donkey anti-goat IgG-AF594 (Invitrogen), Texas Red-conjugated donkey anti-rabbit IgG secondary Ab, and rabbit control IgG Ab (all from Jackson Immunoresearch). Histopathology and immunohistochemistry. Five micron-thick melanoma cryosections were fixed in 220 uC acetone for 5 min. Air-dried sections were incubated with 10 mg ml 21 ABCB5 mAb or 2.5 mg ml 21 CD11b mAb at 4 uC overnight; 10 or 2.5 mg ml 21 mouse IgG were used as negative controls. Sections were washed with PBS 3 times for 5 min each and incubated with 1:200 peroxidase-conjugated secondary Abs for ABCB5 or CD11b staining. For ABCB5/VE-cadherin, ABCB5/TIE1, or ABCB5/CD31 fluorescence double labelling, 5 mm melanoma sections were fixed in 220 uC acetone for 5 min. Airdried sections were incubated with 10 mg ml 21 ABCB5 mAb and 2.5 mg ml 21 VEcadherin, TIE1 or CD31 Abs at 4 uC overnight; 10 mg ml 21 mouse IgG and 2.5 mg ml 21 rabbit IgG were used as negative controls. Sections were washed three times with PBS containing 0.05% Tween 20 for 5 min each and incubated with a 1:150 dilution of Texas Red-conjugated or AF594-conjugated secondary Abs and FITC-conjugated rabbit anti-mouse IgG Ab for 30 min at room temperature. After subsequent washings, the sections were mounted with VECTASHIELD mounting medium (Vector Laboratories) and covered with a cover slip. Immunofluorescence reactivity was viewed on an Olympus BX51/52 system microscope coupled to a Cytovision system (Applied Imaging). Tissue microarray design and analysis. The Melanocytic Tumour Progression tissue microarray (TMA) is the product of a joint effort of three Skin SPORES (Harvard Medical School, MD Anderson Cancer Center, University of Pennsylvania). This array contains 480 3 0.6 mm cores of tumour tissue representing four major diagnostic tumour types: benign nevi, primary cutaneous melanoma, lymph node metastasis and visceral metastasis. Cases were collected from the Pathology services of the three participating institutions. For quality control purposes, two duplicate cores are chosen at each distinct region. Nevi and primary melanomas had either one region or three regions of the tissue block sampled (2 or 6 cores), whereas metastatic tumours had one region sampled from each block. Therefore, the 480 cores represent 2 adjacent cores from 240 distinct histological regions. This array includes 130 cores from 35 nevi, 200 cores from 60 primary melanoma and 150 cores from 75 metastatic lesions. Operationally, thin nevi and thin melanomas involved only the superficial/ papillary dermis, whereas thick nevi and thick melanomas had grown to involve both papillary and deep (reticular) dermis. This array was constructed in the laboratory of M. Rubin. Histological sections of the tissue array slide were baked at 58 uC for 20 min and then treated with the following: xylene (twice for 1 h, then 10 min), 100% ethanol twice for 2 min, 95% ethanol for 2 min, and dH 2 O three times for 2 min. Antigen retrieval was performed in 10 mmol l 21 citrate buffer, pH 6.0 with boiling in a pressure cooker for 10 min and then cooling to room temperature. After washing with PBS twice for 5 min, tissue was blocked with 10% horse serum and 1% BSA in PBS at room temperature for 1 h then incubated with 5 mg ml 21 ABCB5 mAb at 4 uC overnight. The tissue was then washed three times with PBS-0.05% Tween 20 for 5 min then treated with 3% H 2 O 2 /PBS for 15 min. After rinsing in PBS, the sections were incubated with 1:200 biotinylated horse anti-mouse IgG Ab at room temperature for 30 min, rinsed in PBS-Tween three times for 5 min, and incubated with avidin-biotinhorseradish peroxidase complex (Vector Laboratories) for 30 min at room temperature. Immunoreactivity was detected using NovaRed substrate (Vector Laboratories). The Chromavision Automated Cellular Imaging System (ACIS) was used to quantify the immunostaining intensity of ABCB5 and mIgGIR on the HTMA 84 tissue microarray. The control slide intensity values (background plus intrinsic melanization) were subtracted from the experimental slide and the difference in the intensity values for each core was taken to be the true staining. The graph in Fig. 1a shows with 95% confidence interval the difference in intensity for each pathology diagnosis. P values between relevant groups were calculated using the independent/samples t-test. The number above each error bar shows the number of cases within each group. Flow cytometric analysis. Analysis of ABCB5, CD20, CD31, CD45, VEcadherin, BMPR1A, nestin, or TIE1 expression, or of co-expression of ABCB5 with the CD20, CD31, VE-cadherin or BMPR1A surface markers or the nestin or TIE1 intracellular markers in clinical patient-derived melanoma cell suspensions or in G3361 melanoma cells was performed by single-or dual-colour flow cytometry, as described previously 7 . Co-expression analyses of ABCB5 with the above-listed markers in single-cell suspensions derived from G3361/EYFP tumour xenografts and expression analyses of ABCB5 in G3361/DsRed-G3361/ EYFP-derived tumours were performed by triple-colour flow cytometry, gating on EYFP-expressing melanoma cells or ABCB5-expressing cells, respectively. Clinical melanoma cells were incubated with anti-ABCB5 mAb or isotype control mAb or no Ab followed by counterstaining with APC-conjugated donkey anti-mouse IgG. Cells were then fixed in PBS containing 2% paraformaldehyde (30 min at 4 uC), and subsequently incubated with PE-conjugated anti-CD20, anti-CD31, anti-VE-cadherin, anti-nestin or PE-conjugated isotype control mAbs, or unconjugated anti-BMPR1A, anti-TIE1 or unconjugated isotype control mAbs followed by counterstaining with PE-or FITC-conjugated antiimmunoglobulin secondary antibodies. Washing steps with staining buffer or 1% saponin permeabilization buffer were performed between each step. Dual-or triple-colour flow cytometry was subsequently done with acquisition of fluorescence emission at the Fl1 (FITC, EYFP) and/or Fl2 (PE, DsRed) and Fl4 (APC) spectra on a Becton Dickinson FACScan (Becton Dickinson), as described 7 . Statistical differences between expression levels of the above-listed markers by ABCB5 1 and ABCB5 2 patient-derived melanoma cells were determined using the nonparametric Mann-Whitney test. A two-sided P value of P , 0.05 was considered significant. Cell isolation. Single-cell suspensions were generated from human melanoma xenografts on surgical dissection of tumours from euthanized mice. Each tumour was cut into small pieces (, 1 mm 3 ) and tumour fragments were subsequently incubated in 10 ml sterile PBS containing 0.1 g l 21 calcium chloride and 5 mg ml 21 Collagenase Serva NB6 (SERVA Electrophoresis GmbH) for 3 h at 37 uC on a shaking platform at 200 r.p.m. to generate single-cell suspensions. Subsequently, tumour cells were washed with PBS for excess collagenase removal. ABCB5
1 -purified (ABCB5 1) cells were isolated by positive selection and ABCB5
-depleted (ABCB5
2 ) cell populations were generated by removing ABCB5 1 cells using anti-ABCB5 mAb labelling and magnetic-bead cell sorting as described 4, 7, 14 . Briefly, human G3361 melanoma cells or single-cell suspensions derived from human melanoma xenografts or clinical melanoma samples were labelled with anti-ABCB5 mAb (20 mg ml
21
) for 30 min at 4 uC, washed for excess antibody removal, followed by incubation with secondary anti-mouse IgG mAb-coated magnetic microbeads (Miltenyi Biotec) and subsequent dualpassage cell separation in MiniMACS separation columns (Miltenyi Biotec), according to the manufacturers recommendations. Purity of ABCB5 1 and ABCB5
2 (ABCB5 1 cell-depleted) clinical melanoma cell isolates or of ABCB5 1 and ABCB5 2 cell isolates derived from ABCB5 1 patient cell-derived primary melanoma xenograft cells was assayed following magnetic-bead cell sorting by incubation with FITC-conjugated goat anti-mouse IgG secondary Ab and subsequent flow cytometric analysis of ABCB5 expression. ABCB5 1 cell purification resulted in 10.4-fold enrichment of ABCB5 1 melanoma cell frequency from 8.9 6 1.4% in unsegregated samples to 92.4 6 2.8% (mean 6 s.e.m., P , 0.001, Supplementary Fig. 2a) . Negative selection for ABCB5
1 cells resulted in 6.7-fold depletion of ABCB5
1 cell frequency to 1.3 6 0.6% (mean 6
